The future of fulvestrant ('Faslodex')

Cancer Treatment Reviews

Volumn 31, Issue SUPPL. 2, 2005, Pages

  Howell, Anthony ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Aromatase inhibitors; Clinical trials; Fulvestrant; Gefitinib; Receptor cross talk; Trastuzumab

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; ESTROGEN RECEPTOR; EXEMESTANE; FULVESTRANT; GEFITINIB; LAPATINIB; LETROZOLE; MITOGEN ACTIVATED PROTEIN KINASE; PLACEBO; PROGESTERONE RECEPTOR; RECEPTOR BLOCKING AGENT; SOMATOMEDIN C RECEPTOR; TAMOXIFEN; TRASTUZUMAB; VOROZOLE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTHRITIS; ARTHROPATHY; ARTICLE; BONE DISEASE; BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; ENDOMETRIUM CANCER; EVIDENCE BASED MEDICINE; FUTUROLOGY; HUMAN; OSTEOARTHRITIS; OSTEOLYSIS; POSTMENOPAUSE; PROTEIN DEGRADATION; THROMBOEMBOLISM; TREATMENT FAILURE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; POSTMENOPAUSE; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN;

EID: 27144495766     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2005.08.007     Document Type: Article

References (37)

1. Early Breast Cancer Trialists' Collaborative Group Tamoxifen for early breast cancer: An overview of the randomised trials Lancet 351 1998 1451-1467
2. A. Howell Preliminary experience with pure antiestrogens Clin Cancer Res 7 Suppl 2001 4369s-4375s
3. J.M. Nabholtz A. Buzdar M. Pollak et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial. Arimidex Study Group J Clin Oncol 18 2000 3758-3767
4. H. Mouridsen M. Gershanovich Y. Sun et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group J Clin Oncol 21 2003 2101-2109
5. R. Paridaens L. Dirix C. Lohrisch et al. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer Ann Oncol 14 2003 1391-1398
6. ATAC Trialists' Group Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer Lancet 365 2005 60-62
7. P.E. Goss J.N. Ingle S. Martino et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer N Engl J Med 349 2003 1793-1802
8. R.C. Coombes E. Hall L.J. Gibson et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer N Engl J Med 350 2004 1081-1092
9. S.M. Campos Aromatase inhibitors for breast cancer in postmenopausal women Oncologist 9 2004 126-136
10. A.E. Wakeling Similarities and distinctions in the mode of action of different classes of antioestrogens Endocr Relat Cancer 7 2000 17-28
11. S. Addo R.A. Yates A. Laight A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers Br J Cancer 87 2002 1354-1359
12. A. Howell J.F.R. Robertson J. Quaresma Albano et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment J Clin Oncol 20 2002 3396-3403
13. C.K. Osborne J. Pippen S.E. Jones et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trial J Clin Oncol 20 2002 3386-3395
14. J.F. Robertson C.K. Osborne A. Howell et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women - a prospective combined analysis of two multicenter trials Cancer 98 2003 229-238
15. C.M. Chan L.A. Martin S.R. Johnston S. Ali M. Dowsett Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation J Steroid Biochem Mol Biol 81 2002 333-341
16. L. Perey R. Paridaens F. Nolé Fulvestrant (Faslodex™) as hormonal treatment in postmenopausal patients with advanced breast cancer (ABC) progressing after treatment with tamoxifen and aromatase inhibitors: Update of a phase II SAKK trial Breast Cancer Res Treat 88 Suppl 1 2004 S236 [abstract 6048]
17. Ingle JN, Rowland KM, Suman VJ, et al. Evaluation of fulvestrant in women with advanced breast cancer and progression on prior aromatase inhibitor therapy: A phase II trial of the North Central Cancer Treatment Group. In: Poster presentation at the San Antonio Breast Cancer Symposium, 8-11 December 2004, San Antonio, Texas, USA (poster 409).
18. J.M.W. Gee M.E. Harper I.R. Hutcheson et al. The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro Endocrinology 144 2003 5105-5117
19. R.J. Pietras D.C. Marquez H.W. Chen R. Ayala L.B. Ramos D.J. Slamon Improved antitumor therapy with Herceptin and Faslodex for dual targeting of HER-2 and estrogen receptor signalling pathways in human breast cancers with overexpression of HER-2/neu gene Breast Cancer Res Treat 82 Suppl 1 2003 S12 [abstract 22]
20. L.-A. Martin I. Farmer S.R.D. Johnston S. Ali C. Marshall M. Dowsett Enhanced estrogen receptor (ER) α, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation J Biol Chem 278 2003 30458-30468
21. S.A. Massarweh S. Jiang S.K. Mohsin et al. Resistance to endocrine therapy in a xenograft model of HER-2 over expressing breast cancer is accompanied by increased HER-2 but loss of IGF-1 receptor expression Breast Cancer Res Treat 87 Suppl 1 2003 [abstract 1007]
22. J.N. Ingle K.M. Rowland V.J. Suman et al. Evaluation of fulvestrant in women with advanced breast cancer and progression on prior aromatase inhibitor therapy: A phase II trial of the North Central Cancer Treatment Group Breast Cancer Res Treat 88 Suppl 1 2004 S38 [abstract 409]
23. S. Franco A. Perez E. Tan-Chiu C. Frankel C.L. Vogel Response to fulvestrant in heavily pretreated postmenopausal women: A single-center experience Breast Cancer Res Treat 88 2004 103-108
24. L. Petruzelka M. Zimovjanova B. Konopasek P. Mares Z. Dlouha Fulvestrant in postmenopausal women with metastatic breast cancer progressing on prior endocrine therapy - updated results from an expanded access programme Ann Oncol 15 Suppl 3 2004 iii36 [abstract 136P]
25. G. Steger R. Bartsch C. Wenzel et al. Fulvestrant (Faslodex®) in metastatic breast cancer Breast Cancer Res Treat 82 Suppl 1 2003 S104 [abstract 437]
26. P.E. Lønning E. Bajetta R. Murray et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: A phase II trial J Clin Oncol 18 2000 2234-2244
27. E.R. Levin Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor Mol Endocrinol 17 2003 309-317
28. R.J. Pietras Interactions between estrogen and growth factor receptors in human breast cancers and the tumor-associated vasculature Breast J 9 2003 361-373
29. S.R.D. Johnston J. Head S. Pancholi et al. Integration of signal transduction inhibitors with endocrine therapy: An approach to overcoming hormone resistance in breast cancer Clin Cancer Res 9 Suppl 2003 524s-532s
30. A. Sommer J. Hoffmann R.B. Lichtner M.R. Schneider K. Parczyk Studies on the development of resistance to the pure antiestrogen Faslodex in three human breast cancer cell lines J Steroid Biochem Mol Biol 85 2003 33-47
31. R.A. McClelland D. Barrow T.A. Madden et al. Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex) Endocrinology 142 2001 2776-2788
32. C. Dati S. Antoniotti D. Taverna I. Perroteau M. De Bortoli Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells Oncogene 5 1990 1001-1006
33. L.D. Read D. Keith Jr. D.J. Slamon B.S. Katzenellenbogen Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines Cancer Res 50 1990 3947-3951
34. C.C. Benz G.K. Scott J.C. Sarup et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu Breast Cancer Res Treat 24 1993 85-95
35. R.J. Pietras J. Arboleda D.M. Reese et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells Oncogene 10 1995 2435-2446
36. J.F. Robertson B. Erikstein K.C. Osborne et al. Pharmacokinetic profile of intramuscular fulvestrant in advanced breast cancer Clin Pharmacokinet 43 2004 529-538
37. J.F. Robertson R.I. Nicholson N.J. Bundred et al. Comparison of the short-term biological effects of